Stockreport

Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF ZEJULA is a potential best-in-class PARP inhibitor for ovarian cancer patients due to its compelling clinical data1, once-daily dosing and pharmacokinetic properties ZE [Read more]